xCELLigence RTCA CardioECR by ACEA Biosciences – A part of Agilent

Manufacturer ACEA Biosciences – A part of Agilent  |  Available Worldwide
4.3
/
5.0
  |  5 reviews
Cardiomyocyte contractility, viability, and electrical activity measured in real-time. The new xCELLigence® RTCA CardioECR instrument combines high frequency measurement of cell-induced electrical impedance with multielectrode array technology to simultaneously assess cardiomyocyte contractility, viability, and electrophysiology.  This model is similar to our other xCELLigence instruments in its use of noninvasive electrical impedance monitoring to asses cellular morphology change and attachm... Read more


xCELLigence RTCA CardioECR by ACEA Biosciences – A part of Agilent product image
xCELLigence RTCA CardioECR
Request Pricing

Receive your quote directly from the manufacturer.




Average Rating: 4.3
5 Scientists have reviewed this product

5 out of 5
Ease of use
5 out of 5
After sales service
4 out of 5
Value for money


  • Status:

    Reviewer
  • Member since: 2018

  • Organization: Industry



  • Ease of use
    5 out of 5
    After sales service
    4 out of 5
    Value for money
    3 out of 5
Satisfying equipment, but much better if more people use it.
Rating: 4.0

  • Application Area: Drug toxicity screening

"The equipment is very easy to use for data acquisition. The staff are kind and supportive so I'm satisfied with after sales-care. However, I feel that the machine and E-plate are a little bit expensive for everyone to routinely use. I'm basically satisfied with data quality and reproducibility, but maybe related with cell quality, in some cases we cannot obtain the same results as those in other types of equipment (like microelectrode array)."

Review date: 23 Jul 2018 | xCELLigence RTCA CardioECR
  • Status:

    Reviewer

  • Member since: 2018

  • Organization: Hospital for Sick Children



  • Ease of use
    4 out of 5
    After sales service
    5 out of 5
    Value for money
    4 out of 5
Novel method of analysis
Rating: 4.3

  • Application Area:cardiac functional testing

"Easiest and most reproducible instrument for this experiment type."

Review date: 18 Jul 2018 | xCELLigence RTCA CardioECR
  • Status:

    Reviewer

  • Member since: 2015

  • Organization: University of Cologne



  • Ease of use
    5 out of 5
    After sales service
    4 out of 5
    Value for money
    3 out of 5
This system possesses some useful properties such as noninvasive, continuous monitoring of changes in beating activities during compound exposure, which are unique to its design. Therefore, can be easily applied to screen for potential problems with promising drug candidates at an early stage of their development.
Rating: 4.0

  • Application Area:Electrophysiology, Toxicity

"xCELLigence provide an exceptionally diverse pattern of functional endpoints, each with the robustness characteristics required to support drug development process and screening. It is a sophisticated platform with sufficient and accurate recording capacity for key physiological and biochemical changes in the cells. It also allows for functional monitoring of the manufacturing process and label-free assessment of the physiological status of beating cells as well as the detection of both short- and long-term responses to compound exposure."

Review date: 25 Jan 2016 | xCELLigence RTCA CardioECR
  • Status:

    Reviewer

  • Member since: 2015

  • Organization: AITHM



  • Ease of use
    4 out of 5
    After sales service
    5 out of 5
    Value for money
    4 out of 5
Rating: 4.3

  • Application Area:analysing heart specific toxins

"I was surprised at how easy it was to use considering the incredible amount of data that the xCELLigence CadioECR obtains. The after analysis was all contained within the software and I was fairly fluent after very minimal training. I guess the only difficulty is that the cells need to grow for several weeks before use and so it is not ideal for infrequent use. Value for money is hard to measure as it is very expensive set up and high cost cells and consumables for a research lab but amazing at what it does and nothing else compares. So, expensive but worth it."

Review date: 05 Aug 2015 | xCELLigence RTCA CardioECR
  • Status:

    Reviewer

  • Member since: 2015

  • Organization: University of California, San Diego



  • Ease of use
    5 out of 5
    After sales service
    5 out of 5
    Value for money
    5 out of 5
Rating: 5.0

  • Application Area:Simultaneous measurement of contractility and field potentials in iPS-derived cardiomyocytes

"The ACEA Cardio ECR system is very easy and convenient to use, and allows for very informative readouts in a high throughput fashion. The system has good sensibility and is adequate for a quick and dual evaluation of small molecules that cause changes in beating rhythm and induce arrhythmogenic behaviour and/or cardiotoxicity. The ACEA support team has been stellar in their help setting up the system, training personnel and assisting with data analysis and interpretation."

Review date: 07 Jul 2015 | xCELLigence RTCA CardioECR

Cardiomyocyte contractility, viability, and electrical activity measured in real-time.

The new xCELLigence® RTCA CardioECR instrument combines high frequency measurement of cell-induced electrical impedance with multielectrode array technology to simultaneously assess cardiomyocyte contractility, viability, and electrophysiology.  This model is similar to our other xCELLigence instruments in its use of noninvasive electrical impedance monitoring to asses cellular morphology change and attachment quality in a label-free and real-time manner.  Because cell-induced electrical impedance is dependent on cell size/shape and how strongly the cell interacts with the plate bottom, the contraction-relaxation cycle of cardiomyocytes gives rise to a distinct, rhythmic fluctuation in impedance that is readily captured on this time scale.  Changes in the intensity and periodicity of this “beating” pattern can be monitored in the short (seconds) to long (days) time regimes to assess cardiomyocyte contractility and viability in the presence of different drugs.  The CardioECR (ExtraCellular Recording) model differs from our other xCELLigence instruments, including the first generation Cardio model, in the following ways: (1) It has an enhanced impedance data acquisition rate (every 1 millisecond), (2) it uses a separate pair of electrodes to measure field potential at 10 kHz, (3) it provides a pacing stimulus, and (4) it uses an electronic 48-well microtiter plate (E-Plate® CardioECR 48).  The simultaneous recording of impedance and field potential by the xCELLigence RTCA CardioECR instrument provides a view of cardiomyocyte health at an unprecedented level of detail, enabling a deeper understanding of the mechanisms underlying drug-induced cardiac liability.  

The xCELLigence RTCA CardioECR instrument is placed in a standard CO2 cell culture incubator and interfaces via a cable with analysis and control units that are housed outside the incubator.  User friendly software allows for real-time control and monitoring of the instrument, and includes real-time data display and analysis functions.

The xCELLigence RTCA CardioECR instrument, regularly used in combination with human iPSC-derived cardiomyocytes, enables in vitro assays that are highly predictive of drug induced cardiac liability.  It offers:

  • A high-throughput method for detecting functional cardiotoxicity (effects on short-term and long-term cardio beating activity) and general toxicity in vitro
  • A test of integrated ion channel activity
  • Data that display excellent correlation with clinical arrhythmogenic risk
  • Pacing function for more tightly controlled assays
  • More thorough understanding of drug mechanism of action

Product Overview

xCELLigence RTCA CardioECR by ACEA Biosciences – A part of Agilent product image

xCELLigence RTCA CardioECR

Manufacturer ACEA Biosciences – A part of Agilent  |  Available Worldwide

4.3 / 5.0 | 5 reviews